Structure of pan-BD2 inhibitor GSK620

BD2 domain selective BET inhibitor

oral efficacy in 3 inflammation models

from SBDD of a BD2-selective HTS hit

Science, Mar. 19, 2020

GlaxoSmithKline, Stevenage, UK

GSK620 (GlaxoSmithKline (GSK) oral in vivo BD2 domain selective BET inhibitor)

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.